We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The device industry has given its mixed blessing to final rules on 2007 reimbursement rates issued by the Centers for Medicare & Medicaid Services (CMS).
Industry groups are criticizing a recent activist report on the state of the Medicare prescription drug plan as a ploy to get direct government negotiation of Medicare costs, a move which they say will limit consumers’ choices.
Industry groups are criticizing a recent activist report on the state of the Medicare prescription drug plan as a ploy to get direct government negotiation of Medicare costs, a move which they say will limit consumers’ choices.
Industry groups are criticizing a recent activist report on the state of the Medicare prescription drug plan as a ploy to get direct government negotiation of Medicare costs, a move which they say will limit consumers’ choices.
Forty-four lawmakers have written to HHS Secretary Mike Leavitt asking him to put the brakes on proposed cuts to the Medicare fee schedule for power mobility devices (PMDs) and accessories, scheduled to go into effect Nov. 15.
To be effective, the unique device identifier (UDI) system proposed by the FDA must work alongside upgrades in hospital IT systems that include the integration of electronic health records (EHRs), experts said at a recent meeting.
The HHS’ Office of Inspector General (OIG) is focusing on ways the federal government can reduce the amount it spends for prescription drugs under Medicaid, including greater use of generics, a high-ranking OIG official says.
Every devicemaker should include a reimbursement strategy in the early stages of device development to ensure the viability of its products, experts said at the annual Regulatory Affairs Professionals Society conference Oct. 18.
The Centers for Medicare & Medicaid Services (CMS) is using a proposed rule issued Oct. 18 to test the legal waters for its plan to collect and share prescription drug plan data so it can base Medicare reimbursements on product comparisons, sources say.
The Centers for Medicare & Medicaid Services (CMS) is using a proposed rule issued today to test the legal waters for its plan to collect and share prescription drug plan data to base Medicare reimbursement on product comparisons, sources say.